(Q50725436)

18 March 2018

title

Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. (English)

1 reference

18 March 2018

0 references

1 reference

1

1 reference

18 March 2018

author name string

Sumithra J Mandrekar

series ordinal

2

1 reference

18 March 2018

publication date

27 August 2013

1 reference

18 March 2018

published in

Clinical Trials

1 reference

18 March 2018

volume

10

1 reference

18 March 2018

issue

5

1 reference

18 March 2018

page(s)

647-652

1 reference

18 March 2018

Multiplicities in cancer research: ubiquitous and necessary evils

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Reducing patient eligibility criteria in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Development of the 21-gene assay and its application in clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Use of archived specimens in evaluation of prognostic and predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

A two-stage Bayesian design for co-development of new drugs and companion diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Phase III clinical trials that integrate treatment and biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774513497125

21 January 2018

Identifiers

DOI

10.1177/1740774513497125

1 reference

18 March 2018

1 reference

18 March 2018